The report covers SINOVAC's Corporate Social Responsibility (CSR) performance for 2022, highlighting the company's commitment to 'Supply Vaccines to Eliminate Human Diseases' through its core business activities, as well as various public welfare initiatives. It details the company's efforts in areas such as R&D, manufacturing, product quality, employee development, and international cooperation, showcasing its dedication to sustainable development and its contribution to public health globally. Key highlights include the company's COVID-19 vaccine reaching over 2.9 billion doses globally, the prequalification of its polio and varicella vaccines by the WHO, the establishment of several international branches and joint ventures, and its charitable donations exceeding RMB 66 million.
